NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

Company

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

Biotechnology Research Haifa, H_efa, Il 24 employees

Employees: 24
Contacts: 3
Emails: 3
Phones: 1

nurexone.com LinkedIn Crunchbase

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Overview

Headquarters: Haifa, H_efa, Il
Website: nurexone.com
Industry: Biotechnology Research
Employees: 24
Founded: 2020
Funding: 1.6M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

jobs

About NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 1; 25.0% coverage

NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Org Chart

Sample employees and titles

Name	Title	Location	Contact
Lior Shaltiel, Phd	Chief Executive Officer at Nurexone	Center District, Israel	Email Phone
Yossi Mograbi		Tel Aviv District, Israel	Email
Shulamit Levenberg	Professor at the Technion - Israel		View
Sharon Soueid-Baumgarten	Senior Scientist at Nurexone Biologic	Israel	Email